UCB Gets Complete Response Letter From FDA Regarding Neupro

UCB SA has received a complete response letter from the U.S. Food and Drug Administration (FDA) recommending reformulation of Neupro before making it available in the U.S. market for the treatment of Parkinson's disease and restless legs syndrome.
RTTNews